Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Jain, Ajay ^a,b   Olsen, Henrik S ^c   Vyzasatya, Ravi ^a   Burch, Erin ^a   Sakoda, Yukimi ^a   Mérigeon, Emmanuel Y ^c   Cai, Ling ^d   Lu, Changwan ^d   Tan, Ming ^d   Tamada, Koji ^a   Schulze, Dan ^a   Block, David S ^c   Strome, Scott E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c Gliknik Inc   (United States)

^d UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C TYPE LECTIN SIGN R1; DEXAMETHASONE; FC RECEPTOR; FC RECEPTOR I; FC RECEPTOR IIB; FC RECEPTOR IV; HOMODIMER; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G2A; ISOLEUCINE; LECTIN; LEUCINE ZIPPER PROTEIN; POLYMER; PREDNISOLONE; RECOMBINANT IMMUNOGLOBULIN G2A FC FRAGMENT; STRADOMER; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; GOLD STANDARD; GRAFT VERSUS HOST REACTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERFEROMETRY; MORNING DOSAGE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; THROMBOCYTE COUNT; ANIMAL; ARTHRITIS, EXPERIMENTAL; C57BL MOUSE; DBA MOUSE; KNOCKOUT MOUSE; METABOLISM; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZATION; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, EXPERIMENTAL; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOM ALLOCATION; RECEPTORS, IGG; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84865054691     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4024     Document Type: Article

References (31)

1. Morgan EL, Tempelis CH. The requirement for the Fc portion of antibody in antigen-antibody complex-mediated suppression. J Immunol 1978, 120:1669-1671.
2. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?. J Clin Invest 2005, 115:155-160. 539200, 15630455.
3. Deng R, Balthasar JP. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood 2007, 109:2470-2476. 10.1182/blood-2006-04-018093, 1852190, 17132715.
4. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JGJ, Hack CE, Bleeker WK. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001, 98:1095-1099. 10.1182/blood.V98.4.1095, 11493456.
5. Bazin R, Lemieux R, Tremblay T, St-Amour I. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent phagocytosis of blood cells. Br J Haematol 2004, 127:90-96. 10.1111/j.1365-2141.2004.05105.x, 15384982.
6. Augener W, Friedman B, Brittinger G. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)?. Blut 1985, 50:249-252. 10.1007/BF00320302, 3845820.
7. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect [see comments]. Blood 1991, 77:1884-1893.
8. Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. Jf Immunol 2003, 170:3134-3138.
9. Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, Fodor S, Kelner DN, Flynn GC, Liu YD, Bondarenko PV, Ricci MS, Dillon TM, Balland A. Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 2008, 283:16194-16205. 10.1074/jbc.M709987200, 3259661, 18339624.
10. Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit, Balland A, Bonderanko PV. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008, 283:16206-16215. 10.1074/jbc.M709988200, 3259628, 18339626.
11. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999, 162:3749-3752.
12. Horton RM, Cai ZL, Ho SN, Pullen JK, Hunt HD, Cai Z, Pease LR. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques 1990, 8:528-535.
13. Xu Y, Flies AS, Flies DB, Zhu G, Anand S, Flies SJ, Xu H, Anders RA, Hancock WW, Chen L. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood 2007, 109:4097-4104. 10.1182/blood-2006-09-047332, 1874563, 17179227.
14. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003, 101:3708-3713. 10.1182/blood-2002-10-3078, 12506021.
15. Morris NP, Peters C, Montler R, Hu H-M, Curti BD, Urba WJ, Weinberg AD. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol 2007, 44:3112. 10.1016/j.molimm.2007.02.004, 1950941, 17374396.
16. Luo Y, Lu Z, Raso SW, Entrican C, Tangarone B. Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcγ receptors. mAbs 2009, 1:491-504. 10.4161/mabs.1.5.9631, 2759499, 20065648.
17. Anthony RM, Wermeling F, Karlsson MCI, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008, 105:19571-19578. 10.1073/pnas.0810163105, 2604916, 19036920.
18. van Mirre E, Teeling JL, van der Meer JWM, Bleeker WK, Hack CE. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcÎ3RII and FcÎ3RIIIb. J Immunol 2004, 173:332-339.
19. Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol 2007, 19:646-651. 10.1016/j.coi.2007.09.004, 18032008.
20. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008, 359:307-309. 10.1056/NEJMcibr0803649, 18635437.
21. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007, 204:11-15. 10.1084/jem.20061788, 2118416, 17227911.
22. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003, 101:3708-3713. 10.1182/blood-2002-10-3078, 12506021.
23. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007, 7:715. 10.1038/nri2155, 17703228.
24. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486. 10.1126/science.291.5503.484, 11161202.
25. Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc[gamma] receptors on dendritic cells. Nat Med 2006, 12:688. 10.1038/nm1416, 16715090.
26. Morgan EL, Tempelis CH. The role of antigen-antibody complexes in mediating immunologic unresponsiveness in the chicken. J Immunol 1977, 119:1293-1298.
27. Virgin HW, Unanue ER. Suppression of the immune response to Listeria monocytogenes. I. Immune complexes inhibit resistance. J Immunol 1984, 133:104-109.
28. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376. 10.1126/science.1154315, 2409116, 18420934.
29. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673. 10.1126/science.1129594, 16888140.
30. Muscat C, Bertotto A, Ercolani R, Bistoni O, Agea E, Cesarotti M, Fiorucci G, Spinozzi F, Gerli R. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis 1995, 54:382-385. 10.1136/ard.54.5.382, 1005599, 7794045.
31. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?. J Clin Invest 2005, 115:155-160. 539200, 15630455.